Enhertu plus Pertuzumab granted priority review in the US as 1st-line treatment for patients with...

Huadong Medicine’s CDH17-targeted ADC HDM2017 IND application received FDA approval in the US

Qurient and Synaffix partner to develop next-generation dual-payload ADCs

TegMine Therapeutics enters collaboration with Boehringer Ingelheim to advance Novel 2-Factor antibody system for cancer

Mabwell Bioscience, Insilico Medicine, and ChemExpress forging ahead with ADC innovation through strategic collaboration

Hengrui Pharma and Glenmark Pharmaceuticals enter exclusive license agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)